Stock Track | BridgeBio Pharma Plunges 5.16% in Pre-market on $500 Million Convertible Bond Offering

Stock Track

Feb 25, 2025

BridgeBio Pharma, Inc. (BBIO) stock experienced a 5.16% pre-market plunge on Tuesday, as the biopharmaceutical company announced a $500 million private offering of convertible senior notes due in 2029.

The company plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, BridgeBio intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the convertible bond purchasers, with the rest allocated for general corporate purposes.

The announcement of the convertible debt offering, which could potentially dilute existing shareholders, appears to have contributed to the pre-market decline in BridgeBio's stock price. However, the company's recent fourth-quarter revenue beat, driven by strong sales of its rare heart disease drug Attruby (Beyonttra in the EU), may provide some optimism for investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1154153957"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154153957\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154153957?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154153957","market":"hk","top_or_hot":-1,"title":"Stock Track | BridgeBio Pharma Plunges 5.16% in Pre-market on $500 Million Convertible Bond Offering","media":"Stock Track","content":"<p>BridgeBio Pharma, Inc. (BBIO) stock experienced a 5.16% pre-market plunge on Tuesday, as the biopharmaceutical company announced a $500 million private offering of convertible senior notes due in 2029.</p>\n\n<p>The company plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, BridgeBio intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the convertible bond purchasers, with the rest allocated for general corporate purposes.</p>\n\n<p>The announcement of the convertible debt offering, which could potentially dilute existing shareholders, appears to have contributed to the pre-market decline in BridgeBio's stock price. However, the company's recent fourth-quarter revenue beat, driven by strong sales of its rare heart disease drug Attruby (Beyonttra in the EU), may provide some optimism for investors.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BridgeBio Pharma Plunges 5.16% in Pre-market on $500 Million Convertible Bond Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BridgeBio Pharma Plunges 5.16% in Pre-market on $500 Million Convertible Bond Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BridgeBio Pharma, Inc. (BBIO) stock experienced a 5.16% pre-market plunge on Tuesday, as the biopharmaceutical company announced a $500 million private offering of convertible senior notes due in 2029.</p>\n\n<p>The company plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, BridgeBio intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the convertible bond purchasers, with the rest allocated for general corporate purposes.</p>\n\n<p>The announcement of the convertible debt offering, which could potentially dilute existing shareholders, appears to have contributed to the pre-market decline in BridgeBio's stock price. However, the company's recent fourth-quarter revenue beat, driven by strong sales of its rare heart disease drug Attruby (Beyonttra in the EU), may provide some optimism for investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"","article_id":"1154153957","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154153957","pubTimestamp":1740492987,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BridgeBio Pharma, Inc.  stock experienced a 5.16% pre-market plunge on Tuesday, as the biopharmaceutical company announced a $500 million private offering of convertible senior notes due in 2029.The company plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, BridgeBio intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc."},"translate_title":"股票轨迹BridgeBio Pharma发行5亿美元可转换债券盘前暴跌5.16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1},"content_text":"BridgeBio Pharma, Inc. (BBIO) stock experienced a 5.16% pre-market plunge on Tuesday, as the biopharmaceutical company announced a $500 million private offering of convertible senior notes due in 2029.\nThe company plans to use a portion of the net proceeds from the offering to repay all outstanding borrowings under its existing loan agreement with lenders and Blue Owl Corporation. Additionally, BridgeBio intends to use up to $50 million of any remaining proceeds to repurchase its common stock from the convertible bond purchasers, with the rest allocated for general corporate purposes.\nThe announcement of the convertible debt offering, which could potentially dilute existing shareholders, appears to have contributed to the pre-market decline in BridgeBio's stock price. However, the company's recent fourth-quarter revenue beat, driven by strong sales of its rare heart disease drug Attruby (Beyonttra in the EU), may provide some optimism for investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}